Next-generation multitarget stool DNA testing
Next-generation multitarget stool DNA testing has been studied in 2 papers since 2026: none in people yet, 1 review; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 30, 2026: “Evolution of Colorectal Cancer Screening Technologies and Health Economic Evaluation: Optimization Strategies Based on an Economic Gradient and…”.
2 papers study it5 findingsUpdated
1 new paper in 30 daysSee all 2
- In silico1
What did studies of Next-generation multitarget stool DNA testing find?
5Studies of Next-generation multitarget stool DNA testing measured 5 outcomes; the most studied are Colorectal cancer detection sensitivity (1 study), life-years gained (1) and colorectal cancer mortality (1).
Colorectal cancer detection sensitivity
upin humans1
1 study
Colorectal cancer detection sensitivity
upin humans1
Next-generation multitarget stool DNA testing increases colorectal cancer detection sensitivity in humans (compared with fecal immunochemical testing in the same head-to-head cohort) (Sensitivity 93.9% versus 67.3% for FIT).
“next-generation multitarget stool DNA testing achieves a sensitivity of 93.9% for CRC (versus 67.3% for the fecal immunochemical test [FIT] in the same head-to-head cohort)”
Reviewcompared with fecal immunochemical testing in the same head-to-head cohortnext-generation
Frontiers in medicine
Life-years gained
upin silico1
1 study
Life-years gained
upin silico1
Next-generation multitarget stool DNA testing increases life-years gained in silico (+62% life-years gained vs colonoscopy).
“ng mt-sDNA achieved greater CRC mortality reduction (33% vs 20%) and 62% more life-years gained, with consistent findings across sensitivity analyses.”
In silico10 years
Journal of medical economics
Colorectal cancer mortality
downin silico1
1 study
Colorectal cancer mortality
downin silico1
Next-generation multitarget stool DNA testing decreases colorectal cancer mortality in silico (33% vs 20% mortality reduction).
“ng mt-sDNA achieved greater CRC mortality reduction (33% vs 20%) and 62% more life-years gained, with consistent findings across sensitivity analyses.”
In silico10 years
Journal of medical economics
Colorectal cancer detection
upin silico1
1 study
Colorectal cancer detection
upin silico1
Next-generation multitarget stool DNA testing increases colorectal cancer detection in silico (+11% CRC cases detected vs colonoscopy).
“Over 10 years per 1,000 individuals offered screening, ng mt-sDNA detected 13% more precancerous lesions and 11% more CRC cases than colonoscopy”
In silico10 years
Journal of medical economics
Precancerous lesions detected
upin silico1
1 study
Precancerous lesions detected
upin silico1
Next-generation multitarget stool DNA testing increases precancerous lesions detected in silico (+13% precancerous lesions detected vs colonoscopy).
“Over 10 years per 1,000 individuals offered screening, ng mt-sDNA detected 13% more precancerous lesions and 11% more CRC cases than colonoscopy”
In silico10 years
Journal of medical economics